SHILPAMED Shilpa Medicare Ltd Investments/Divestments Announcement 2024 - Europe Approval for Amifampridine Tablets Shilpa Medicare Ltd. has received marketing authorization from Germany, EU for Amifampridine Tablets, 10 mg, which is used in the treatment of rare muscle diseases, with sales of about 20 M USD in Europe..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Shilpa Medicare Ltd